Nivolumab Effective as Second-Line Treatment for Advanced Melanoma
September 29th 2014Treatment with nivolumab (Opdivo) demonstrated superior objective response rates (ORR) and longer durations of response compared with chemotherapy in a phase III trial of patients with previously treated advanced metastatic melanoma
Read More